Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands

Kensei Tsuzaka, Yukihiro Matsumoto, Yasumasa Sasaki, Tohru Abe, Kazuo Tsubota, Tsutomu Takeuchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We have reported that Sjögren's syndrome (SS) patients with enlarged exocrine glands (EEG) formerly referred to as Mikulicz's disease were defective with Fas-ligand (FasL) expression in PBL and lacrimal glands (LGs). To investigate the mechanisms of reduced FasL expression in SS patients with EEG, FasL mRNA expression level was determined using real-time PCR. The FasL gene promoter region (from -1197 to -3) was also amplified using PCR and specific primers. Expression of the FasL mRNA in the LGs and PBLs of three SS patients with EEG was significantly decreased. Direct sequencing revealed a heterozygous point mutation (-259T/C) in the FasL gene promoter region in one SS patient with EEG. A luminescent β-galactosidase (β-gal) reporter assay using a pβgal Enhancer Vector demonstrated that β-gal activity from the vector including the mutant (-259C) FasL (pβgal/mFasL) gene promoter region (735±42) was similar (p = 0.13) to that from a pβgal Enhancer Vector without the gene promoter region (603±66). On the other hand, the β-gal activity was significantly lower (p<0.0001) than that from a vector including the wild-type (-259T) FasL (pbeta;gal/wFasL) (3226±148). In conclusion, the down-regulation of FasL in SS patients with EEG may be due to transcriptional regulation, and the point mutation at -259T/C in the FasL gene promoter region may lead to the down-regulation of FasL mRNA expression and the lymphoproliferative process observed in SS patients with EEG.

Original languageEnglish
Pages (from-to)497-502
Number of pages6
JournalAutoimmunity
Volume40
Issue number7
DOIs
Publication statusPublished - 2007 Nov

Fingerprint

Exocrine Glands
Fas Ligand Protein
Down-Regulation
Messenger RNA
Genetic Promoter Regions
Lacrimal Apparatus
Genes
Point Mutation
Mikulicz' Disease
Galactosidases
Real-Time Polymerase Chain Reaction

Keywords

  • Apoptosis
  • Autoimmune lymphoproliferative syndrome
  • Autoimmunity
  • Sjögren's syndrome

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands. / Tsuzaka, Kensei; Matsumoto, Yukihiro; Sasaki, Yasumasa; Abe, Tohru; Tsubota, Kazuo; Takeuchi, Tsutomu.

In: Autoimmunity, Vol. 40, No. 7, 11.2007, p. 497-502.

Research output: Contribution to journalArticle

Tsuzaka, Kensei ; Matsumoto, Yukihiro ; Sasaki, Yasumasa ; Abe, Tohru ; Tsubota, Kazuo ; Takeuchi, Tsutomu. / Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands. In: Autoimmunity. 2007 ; Vol. 40, No. 7. pp. 497-502.
@article{96c27b5577224c4690fcf1389aad3511,
title = "Down-regulation of Fas-ligand mRNA in Sj{\"o}gren's syndrome patients with enlarged exocrine glands",
abstract = "We have reported that Sj{\"o}gren's syndrome (SS) patients with enlarged exocrine glands (EEG) formerly referred to as Mikulicz's disease were defective with Fas-ligand (FasL) expression in PBL and lacrimal glands (LGs). To investigate the mechanisms of reduced FasL expression in SS patients with EEG, FasL mRNA expression level was determined using real-time PCR. The FasL gene promoter region (from -1197 to -3) was also amplified using PCR and specific primers. Expression of the FasL mRNA in the LGs and PBLs of three SS patients with EEG was significantly decreased. Direct sequencing revealed a heterozygous point mutation (-259T/C) in the FasL gene promoter region in one SS patient with EEG. A luminescent β-galactosidase (β-gal) reporter assay using a pβgal Enhancer Vector demonstrated that β-gal activity from the vector including the mutant (-259C) FasL (pβgal/mFasL) gene promoter region (735±42) was similar (p = 0.13) to that from a pβgal Enhancer Vector without the gene promoter region (603±66). On the other hand, the β-gal activity was significantly lower (p<0.0001) than that from a vector including the wild-type (-259T) FasL (pbeta;gal/wFasL) (3226±148). In conclusion, the down-regulation of FasL in SS patients with EEG may be due to transcriptional regulation, and the point mutation at -259T/C in the FasL gene promoter region may lead to the down-regulation of FasL mRNA expression and the lymphoproliferative process observed in SS patients with EEG.",
keywords = "Apoptosis, Autoimmune lymphoproliferative syndrome, Autoimmunity, Sj{\"o}gren's syndrome",
author = "Kensei Tsuzaka and Yukihiro Matsumoto and Yasumasa Sasaki and Tohru Abe and Kazuo Tsubota and Tsutomu Takeuchi",
year = "2007",
month = "11",
doi = "10.1080/08916930701580320",
language = "English",
volume = "40",
pages = "497--502",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands

AU - Tsuzaka, Kensei

AU - Matsumoto, Yukihiro

AU - Sasaki, Yasumasa

AU - Abe, Tohru

AU - Tsubota, Kazuo

AU - Takeuchi, Tsutomu

PY - 2007/11

Y1 - 2007/11

N2 - We have reported that Sjögren's syndrome (SS) patients with enlarged exocrine glands (EEG) formerly referred to as Mikulicz's disease were defective with Fas-ligand (FasL) expression in PBL and lacrimal glands (LGs). To investigate the mechanisms of reduced FasL expression in SS patients with EEG, FasL mRNA expression level was determined using real-time PCR. The FasL gene promoter region (from -1197 to -3) was also amplified using PCR and specific primers. Expression of the FasL mRNA in the LGs and PBLs of three SS patients with EEG was significantly decreased. Direct sequencing revealed a heterozygous point mutation (-259T/C) in the FasL gene promoter region in one SS patient with EEG. A luminescent β-galactosidase (β-gal) reporter assay using a pβgal Enhancer Vector demonstrated that β-gal activity from the vector including the mutant (-259C) FasL (pβgal/mFasL) gene promoter region (735±42) was similar (p = 0.13) to that from a pβgal Enhancer Vector without the gene promoter region (603±66). On the other hand, the β-gal activity was significantly lower (p<0.0001) than that from a vector including the wild-type (-259T) FasL (pbeta;gal/wFasL) (3226±148). In conclusion, the down-regulation of FasL in SS patients with EEG may be due to transcriptional regulation, and the point mutation at -259T/C in the FasL gene promoter region may lead to the down-regulation of FasL mRNA expression and the lymphoproliferative process observed in SS patients with EEG.

AB - We have reported that Sjögren's syndrome (SS) patients with enlarged exocrine glands (EEG) formerly referred to as Mikulicz's disease were defective with Fas-ligand (FasL) expression in PBL and lacrimal glands (LGs). To investigate the mechanisms of reduced FasL expression in SS patients with EEG, FasL mRNA expression level was determined using real-time PCR. The FasL gene promoter region (from -1197 to -3) was also amplified using PCR and specific primers. Expression of the FasL mRNA in the LGs and PBLs of three SS patients with EEG was significantly decreased. Direct sequencing revealed a heterozygous point mutation (-259T/C) in the FasL gene promoter region in one SS patient with EEG. A luminescent β-galactosidase (β-gal) reporter assay using a pβgal Enhancer Vector demonstrated that β-gal activity from the vector including the mutant (-259C) FasL (pβgal/mFasL) gene promoter region (735±42) was similar (p = 0.13) to that from a pβgal Enhancer Vector without the gene promoter region (603±66). On the other hand, the β-gal activity was significantly lower (p<0.0001) than that from a vector including the wild-type (-259T) FasL (pbeta;gal/wFasL) (3226±148). In conclusion, the down-regulation of FasL in SS patients with EEG may be due to transcriptional regulation, and the point mutation at -259T/C in the FasL gene promoter region may lead to the down-regulation of FasL mRNA expression and the lymphoproliferative process observed in SS patients with EEG.

KW - Apoptosis

KW - Autoimmune lymphoproliferative syndrome

KW - Autoimmunity

KW - Sjögren's syndrome

UR - http://www.scopus.com/inward/record.url?scp=39049127459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049127459&partnerID=8YFLogxK

U2 - 10.1080/08916930701580320

DO - 10.1080/08916930701580320

M3 - Article

VL - 40

SP - 497

EP - 502

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 7

ER -